Investigating how Pyk2 affects immune cells and vesicle release in aggressive brain tumors.
Pyk2 regulates extracellular vesicles release in GBM cells and modulates activation of tumor infiltrating myeloid cells
This study is looking at how a protein called Pyk2 affects the immune response in glioblastoma, a tough type of brain cancer, to find new ways to improve treatment for patients like you.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Central Del Caribe NIH-funded |
| Lab location | 1 site (Bayamon, United States) |
| Project ID | NIH-10793667 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain cancer, and aims to understand the role of a protein called Pyk2 in the tumor's immune environment. By studying how Pyk2 influences the release of extracellular vesicles and the behavior of tumor-infiltrating myeloid cells, the research seeks to identify new molecular targets for improving GBM treatment. The approach involves analyzing tumor samples and cell cultures to assess the impact of Pyk2 on immune cell activation and tumor growth. Patients may benefit from insights that could lead to more effective therapies for GBM.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with non-cancerous brain conditions or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the immune response against glioblastoma, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting immune cell interactions in tumors, suggesting that this approach could be effective in glioblastoma as well.
Where this research is happening
Bayamon, United States
- Universidad Central Del Caribe — Bayamon, United States (Active)
Researchers
- Principal investigator: Kucheryavykh, Lilia — Universidad Central Del Caribe
- Study coordinator: Kucheryavykh, Lilia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.